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oston and Cambridge, Massachusetts; and Tel Hashomer, Israel
OBJECTIVES The purpose of this study was to describe the clinical, angiographic, and histological features of
concomitant in-stent restenosis (ISR) and cardiac allograft vasculopathy (CAV) progression.
BACKGROUND Cardiac allograft vasculopathy is a major challenge to long-term success of heart transplan-
tation. Coronary stenting for CAV is hampered by ISR.
METHODS Quantitative coronary angiography compared late lumen loss (LL) at stented and reference,
non-stented segments during 1-year follow-up in post-heart transplant and control athero-
sclerosis patients. Stented and non-stented arteries with CAV were also obtained post-
mortem for immunohistochemical analysis.
RESULTS In 37 stented lesions (25 patients), 1-year binary restenosis occurred in 37.8%. Patients with
ISR had higher long-term cardiac death/myocardial infarction rates than patients without ISR
(53.8% vs. 9.1%, p  0.03). In the same 25 patients, 34 CAV lesions with non-significant
obstructions were identified as reference controls. After 1 year, patients who developed ISR also
had more control lesion LL (0.78  0.38 mm vs. 0.39  0.27 mm, p  0.006) compared to
patients without ISR. In the post-transplant patients, in-stent LL was closely coupled to control
segment LL (R2 0.63, p 0.05). Conversely, in native atherosclerosis patients, ISR and remote
disease progression were not correlated. Histological staining of stented and control arteries from
CAV patients revealed similar pathologies common to ISR and non-intervened CAV segments.
CONCLUSIONS Progression of CAV at non-intervened segments and ISR correlate strongly and share common
histopathology. Optimized treatment for patients with aggressive CAV needs to address the
widespread nature of this disease, even when it presents as an initially focal lesion. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.01.081Cardiol 2006;48:453–61) © 2006 by the American College of Cardiology Foundation
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Pardiac allograft vasculopathy (CAV) continues to be the
ajor therapeutic challenge and poses significant limitations
or long-term survival after heart transplantation (1). Although
ercutaneous coronary intervention (PCI) with stenting ap-
ears to be an attractive treatment for select patients with focal
AV, it does not halt disease progression elsewhere in the
oronary vasculature, and its effect on long-term allograft
urvival remains questionable (2,3). Multiple non-randomized,
ingle-center studies have evaluated the role of PCI (angio-
lasty or stenting) for CAV and have generally demonstrated
xcellent acute results but high restenosis rates (2–7).
See page 462
The pathogenesis of CAV remains poorly defined and is
hought to be a consequence of both immune and non-
mmune processes (1,8,9). Cardiac allograft vasculopathy is
ost commonly associated with diffuse concentric intimal
From the *Cardiovascular Division, Brigham and Women’s Hospital, Harvard
edical School, Boston, Massachusetts; †Heart Institute, Sheba Medical Center, Tel
ashomer, Israel; and the ‡Harvard–MIT Division of Health Sciences and Tech-
ology, Cambridge, Massachusetts.h
Manuscript received July 13, 2005; revised manuscript received January 6, 2006,
ccepted January 9, 2006.yperplasia, involving both epicardial and intramyocardial
oronary arteries, although focal coronary lesions may de-
elop. Histologically, CAV is characterized by inflammatory
ell infiltration and smooth muscle cell hyperplasia with a
aucity of frank atheroma, histological features reminiscent
f the proliferative inflammatory lesions of in-stent reste-
osis (ISR). Success with sirolimus-coated stents for pre-
enting ISR and oral sirolimus for preventing CAV may
lso suggest a pathophysiologic link. Although the patho-
eneses of both allograft vasculopathy and ISR share such
ommon features, they have not been examined concomi-
antly and serially over time in human subjects. Therefore,
he purpose of the present study was to describe the clinical,
ngiographic, and histological features of CAV and ISR
ccurring simultaneously in cardiac transplant recipients. We
ypothesized that the response to coronary stenting after
ardiac transplantation would parallel the course of CAV in
ites distant to stented segments, in a manner not seen in native
therosclerosis (non-CAV) patients undergoing PCI.
ETHODS
atient population. We reviewed medical records of all 30
eart transplant patients who had stent PCI between 1996
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Stent Restenosis and Transplant Vasculopathy August 1, 2006:453–61nd 2002 at Brigham and Women’s Hospital, Boston,
assachusetts (19 patients) and Sheba Medical Center,
el-Hashomer, Israel (11 patients). At both institutions,
nnual surveillance coronary angiography is performed as
outine clinical practice in all heart transplant recipients. Of
he 30 PCI patients, 25 also had 1-year follow-up coronary
ngiography. The remaining 5 patients died before the first
early follow-up angiography and were not included in our
nalysis. Five of the 25 transplant patients underwent
ultivessel PCI (a staged procedure in 3) wherein 2 to 4
esions were stented. Thus, 37 stented lesions in 25 patients
ith angiographic follow-up form the basis for this analysis.
riple-drug immunosuppression consisting of cyclosporine,
zathioprine or mycophenolate mofetil, and prednisone was
sed as the standard regimen at both centers. A control
roup of native coronary atherosclerosis patients undergoing
CI with 9-month angiographic follow-up was collected
rom SIRIUS (Sirolimus-Eluting Stent in de Novo Coro-
ary Lesions Study) (10), a randomized trial comparing
irolimus-eluting stents with bare-metal stents in the U.S.
ndex and follow-up angiographic films from a cohort of 36
are-metal–stented patients, matched to the post-transplant
roup according to stented segment locations, were studied.
ngiographic analysis. All angiograms from post-
ransplant and SIRIUS control patients were analyzed at the
ngiographic Core Laboratory at Brigham and Women’s
ospital by 2 experienced angiographers blinded to
ollow-up outcomes. Qualitative analysis of baseline native
essel morphology was performed using standard criteria
nd the modified American College of Cardiology/American
eart Association lesion complexity score (11,12).
Angiographic analysis included correlation of ISR and
emote CAV or native atherosclerosis progression. For each
atient, the flow-limiting stenosis treated with stenting was
atched with a non–flow-limiting lesion (50% diameter
tenosis [DS]) in a non-intervened allograft artery, with
imilar reference diameter chosen to represent a “control”
esion. The control site was chosen on the baseline angio-
ram, before viewing or analysis of any follow-up angio-
rams (13). One patient with 4 stented lesions had just 2
atched reference segments due to angiographic core lab
echnical issues regarding matching vessel size, location,
Abbreviations and Acronyms
CAV  cardiac allograft vasculopathy
DES  drug-eluting stent
DS  diameter stenosis
ISR  in-stent restenosis
IVUS  intravascular ultrasound
LL  late lumen loss
MI  myocardial infarction
MLD  minimal lumen diameter
PCI  percutaneous coronary intervention
QCA  quantitative coronary angiographynd lesion length. Similarly, another patient undergoing atenting of 3 lesions had just 2 matched reference
egments.
Both stented and control segments were then analyzed on
aseline and follow-up angiograms, and late lumen loss
LL) for each lesion was determined. The Cardiovascular
easurement System (MEDIS, Leiden, the Netherlands)
as used for off-line quantitative cineangiographic analysis.
he filled diagnostic or guiding catheter was used as the
alibration standard.
Reference vessel diameter segments were calculated by
electing a smooth arterial segment 10 mm proximal to the
esion and 10 mm distal to the lesion from 2 orthogonal views
sing quantitative coronary angiography (QCA). The mean
eference segment diameter, mean minimal lumen diameter
MLD), and mean percent DS before, after, and late following
he index procedure were calculated from an average of the 2
ngiographic projections. In addition, the single angiographic
rojection demonstrating the stenosis in its “worst view” was
ecorded. In-lesion MLD measurement was defined as the
ean MLD derived from 2 orthogonal views (by the QCA) in
he treated segment and also included an additional 5 mm of
roximal and distal edge to evaluate any edge effect.
esion success is defined as the attainment of 50%
esidual stenosis (by QCA). Restenosis was defined as
50% in-stent diameter stenosis at the follow-up angio-
ram. Late loss was defined as the difference between the
n-stent MLD at follow-up angiography and the in-stent
LD immediately after the procedure.
Two post-transplant patients (2 stented segments) with
vailable clinical and angiographic follow-up had technically
ncomplete imaging and were excluded from late loss correla-
ion analysis. In addition, 2 stented and 1 reference segments
rom the transplant group and 1 stented segment from the
ative atherosclerosis group were totally occluded at follow-up
ngiography and hence excluded from late loss calculations.
istopathology analysis. Stented and non-stented human
oronary arteries were obtained at post-mortem examina-
ion from 2 patients. Arteries were fixed in 10% neutral
uffered formalin, radiographed, and processed for light
icroscopy by embedding in a methacrylate formulation as
reviously described (14). Multiple 5-m-thick sections
ere cut with a tungsten carbide knife (Delaware Diamond
nives, Wilmington, Delaware) on an automated micro-
ome (Leica, Lasertechnik GmH, Heidelberg, Germany)
rom the proximal and distal ends and the midpoint of each
essel. Histologic sections were stained with hematoxylin-
osin, Verhoeff elastin, Carstair’s fibrin, and Sirius red stain.
ascular inflammatory response was assessed by CD-68
mmunostaining.
tatistical analysis. Normally distributed data are reported
s mean  standard deviation. Differences among categorical
ariables were assessed using the chi-square or Fisher exact test.
he two-sided Fisher exact test was used to assess categorical
ariables when any of the observed responses numbered 5.
n unpaired Student t test was used to define differencesmong continuous variables in sub-groups. The non-
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August 1, 2006:453–61 Stent Restenosis and Transplant Vasculopathyarametric Spearman rank-correlation coefficient was used to
stimate the correlation between the in-stent late loss and
eference segment late loss.
ESULTS
linical and angiographic variables. The 1-year binary
ngiographic restenosis rate in the heart transplant stented
atients was 37.8% (14 of 37 lesions). There were no
ignificant differences in clinical characteristics among pa-
ients who did or did not develop restenosis (Table 1).
imilarly, the medical regimen, cytomegalovirus status, and
Table 1. Demographic, Clinical, Procedural, an
Without In-Stent Restenosis
R
Clinical characteristics
Male (%)
Age (yrs)
At transplant
At stenting
Stenting (yrs post-transplant)
Underlying ischemic cardiomyopathy (%)
Hypertension (%)
Diabetes (treated) (%)
Creatinine at stenting
Left ventricular ejection fraction at stenting (%)
Patients with rejections  grade 3A (%)
Episodes per patient with rejection
Positive CMV serology (%)
Donor
Recipient
CMV disease
Medication (%)
Azathioprine
Mycophenolate mofetil
Cyclosporine
Prednisone
Gancyclovir
Statin
Procedural characteristics
Stented artery (%)
LAD
CX
RCA
Lesion length (mm)
Pre-procedure
RVD (mm)
DS (%)
MLD (mm)
Post-procedure
RVD (mm)
DS (%)
MLD (mm)
Acute gain (mm)
Follow-up
RVD (mm)
DS (%)
MLD (mm)
Late loss (mm)
Late loss indexCMV  cytomegalovirus; CX  circumflex artery; DS  diamete
MLD  minimal lumen diameter; RCA  right coronary artery;umber of rejection episodes requiring increased immuno-
uppression in the year after stenting were comparable
etween the 2 groups. Stented lesions that developed
estenosis tended to have more severe pre-procedure DS
nd smaller MLD. As expected, LL was significantly
reater in restenotic lesions (1.73  0.58 mm vs. 0.46 
.31 mm, p  0.001) (Table 1).
oncurrent ISR and reference vessel disease progression.
LLOGRAFT VASCULOPATHY. In order to evaluate trans-
lant vascular disease progression, a total of 34 lesions in
on-intervened allograft coronary arteries with non-
ngiographic Variables of Patients With and
osis, n  14
Lesions)
No Restenosis, n  11
(23 Lesions)
p
Value
85.7 90.9 1.0
.9  8.0 53.0  8.7 0.09
.4  8.7 58.6  9.0 0.15
.4  2.8 5.6  2.8 0.49
76.9 45.5 0.21
38.5 18.2 0.38
30.8 27.3 1.0
.2  2.2 1.6  0.3 0.35
.7  14.2 51.8  9.7 0.40
69.2 54.5 0.65
.4  1.3 1.1  1.7 0.65
33.3 18.2 0.64
69.2 72.4 1.0
0 0 1.0
92.3 100 1.0
23.1 27.3 1.0
100 100 1.0
84.6 90.9 1.0
0 18.2 1.0
91.7 81.8 0.59
55.6 27.3
16.7 36.4
27.8 36.4 0.29
6  13.09 21.02  7.46 0.48
3  0.43 2.64  0.33 0.13
7  12 80  10 0.08
0  0.3 0.52  0.26 0.04
3  0.33 2.73  0.34 0.41
4  9 14  9 0.98
1  0.37 2.29  0.52 0.59
3  0.69 1.77  0.52 0.46
5  0.38 2.61  0.29 0.22
9  17 26  10 0.001
8  0.39 1.93  0.34 0.001
3  0.58 0.46  0.31 0.001
4  0.30 0.24  0.16 0.01d A
esten
(14
46
53
6
2
47
1
23.9
2.4
8
0.3
2.6
1
2.2
1.7
2.4
7
0.4
1.7
0.9r stenosis; LAD  left anterior descending coronary artery;
RVD  reference vessel diameter.
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Stent Restenosis and Transplant Vasculopathy August 1, 2006:453–61ignificant (50% DS) lumen narrowing were used as
on-PCI control vessels. Characteristics of these non-PCI
esions are shown in Table 2, according to whether reste-
osis developed in the same patient’s stented site. At
aseline, the non-PCI lesions were similar between the 2
roups. At follow-up angiography, the non-PCI lesions
rom transplant patients who developed ISR had more LL
0.78  0.38 mm vs. 0.39  0.27 mm, p  0.006) and
maller MLD compared to the non-PCI lesions of patients
able 2. Characteristics of Reference Lesions, According to
hether Restenosis Developed in Stented Site
Reference of
Restenosis
Lesions, n  13
Reference of
Non-Restenosis
Lesions, n  21
p
Value
re-procedure
RVD (mm) 2.56  0.34 2.64  0.37 0.86
DS (%) 27.70  13.72 22.32  11.18 0.25
MLD (mm) 1.85  0.44 1.97  0.40 0.44
ollow-up
RVD (mm) 2.41  0.45 2.51  0.38 0.5
DS (%) 52.08  29.47 34.81  20.42 0.07
MLD (mm) 1.17  0.80 1.64  0.55 0.07
ate loss (mm) 0.78  0.38 0.39  0.27 0.006
bbreviations as in Table 1.igure 1. Cumulative frequency of minimal luminal diameters (MLDs). The cu
mmediately after stent implantation and at follow-up; (B) reference, non-stentithout ISR (Table 2).
The cumulative frequency distribution curves of MLD
easured at baseline and follow-up, for both PCI segments
nd control non-PCI segments, are shown in Figure 1.
lthough late loss was greater in the stented segments, both
he stented and control segments demonstrate a loss of
LD over time.
For each individual heart transplant patient, in-stent late
oss directly correlated with late loss of the matched control
egment, in both the Sheba Medical Center and the
righam and Women’s patient populations (R2 0.63, p
.05) (Fig. 2A).
ATIVE CORONARY ATHEROSCLEROSIS. In the cohort of
ative atherosclerosis (non-CAV) patients undergoing
CI, the angiographic restenosis rate was 27.8% (10 of 36
esions). As for the post-transplant patients, concurrent
SR and atherosclerotic lesion progression in a non-
ntervened segment were analyzed at baseline and at
ollow-up. Stented lesions that developed restenosis
ended to be longer and have slightly more post-
rocedure DS. As expected, in-stent LL was significantly
reater in restenotic lesions (1.72  0.32 mm vs. 0.57 
.53 mm, p  0.001). At baseline, the control, non-PCImulative frequency distribution curve of MLDs of: (A) stented segment,
ed segment at baseline and at follow-up angiogram.
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August 1, 2006:453–61 Stent Restenosis and Transplant Vasculopathyesions were similar between the 2 groups. Interestingly,
t follow-up angiography, the non-PCI lesions from
atients who developed ISR had similar LL (0.01 
.17 mm) compared to the non-PCI lesions of patients
ithout restenosis (0.03  0.27 mm, p  0.62). All
ative atherosclerosis (non-CAV) patients displayed
inimal progression of atherosclerosis in the non-PCI
egments. This is in marked contrast to the disease
rogression in non-PCI CAV lesions (Table 2). Further-
ore, plotting the in-stent late loss with reference
egment late loss on a patient-by-patient basis failed to
how any correlation (Fig. 2B), in marked contrast to the
ndings in stented CAV patients.
ong-term follow-up. The 14 patients exhibiting in-stent
ngiographic binary restenosis were followed clinically for
9.7  11.1 months after PCI. There were 6 deaths
42.9%), all due to graft organ failure. In contrast, there
igure 2. Scatter plot shows correlation between in-stent late loss and n
B) native atherosclerosis patients. For each individual post-transplant p
ndividual matched non-intervened segment, in both the Sheba Medical
ontrast, no such coupling of in-stent and reference vessel late loss was foere only 2 deaths (18.2%) in the 11 patients free of restenosis, followed for 36.3  18.0 months after PCI. The
auses of death in the non-restenosis group were graft
ailure (n 1) and malignancy (n 1, p 0.06, comparing
ardiac death for patients with and without restenosis).
ospitalization for acute myocardial infarction (MI) oc-
urred in 4 of the ISR patients and in none of the
on-restenosis CAV patients. The combined occurrence of
ardiac death or MI during follow-up was significantly
igher in the group of patients with angiographic ISR
53.8% vs. 9.1%, p  0.03).
istopathology. Stented and non-intervened coronary
egments of 2 patients after heart transplantation were
vailable for detailed histologic analysis.
ASE 1. A 52-year-old, post-heart transplant woman with
AV underwent stenting of a ramus intermedius in No-
ember 2002 (Fig. 3). Repeat angiography in May 2003
tervened, reference segment late loss: (A) heart transplant patients and
, in-stent late lumen loss was closely coupled to late lumen loss of the
er and Brigham and Women’s Hospital (BWH) patient populations. In
n native atherosclerosis patients.on-in
atientevealed focal ISR in the ramus intermedius and significant
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Stent Restenosis and Transplant Vasculopathy August 1, 2006:453–61isease progression in the non-intervened mid- and distal
egments of the left anterior descending coronary artery
Fig. 3). Although both lesions were successfully managed
ith PCI, the patient suffered an anterior MI 7 months later
nd expired.
Histologic examination of the stented ramus intermedius
nd a non-stented diagonal branch artery are shown in
igure 4. Marked neointimal thickening with resultant
arrowing of the bare-metal stent lumen was evident, and
iffuse intimal hyperplasia impinged upon the non-
ntervened diagonal lumen as well. The intimal thickening
esponsible for both lesions (ISR in the ramus intermedius
nd transplant vasculopathy in the diagonal branch) con-
isted of fibrotic, collagen-rich, hypocellular matrix with
ome evidence of inflammatory cell invasion (Fig. 4).
otably, severe adventitial thickening and fibrosis were
resent in both the stented and the non-intervened artery.
ASE 2. A 39-year-old, post-heart transplant man under-
ent left circumflex stenting in 1998 and was noted to have
rogressive CAV and non-critical ISR during follow-up
ngiography. Out-of-hospital sudden death occurred in 2003.
The stented circumflex artery and non-intervened obtuse
arginal branch were available for histological analysis
Fig. 4). Similar to Case 1, severe ISR in the circumflex
rtery and diffuse intimal hyperplasia in the non-stented
btuse marginal branch were evident. Again, histologic
igure 3. Stenting and follow-up angiograms of Case 1: (A) angiogram
rregularities of the reference left anterior descending artery segment (ar
eployment of a bare-metal stent (arrow); (C) repeat angiogram, 6 months af
ignificant disease progression in the non-intervened mid- and distal portions otaining demonstrated a fibrotic, collagen-rich, hypocellular
eointima with inflammatory cells in both the restenotic
esion and the native non-intervened coronary segments.
ISCUSSION
e report a novel strong association between in-stent neoin-
imal proliferation (restenosis) and progression of coronary
rtery disease in patients after heart transplantation, which is
arkedly absent in a control group of stented native athero-
clerosis patients. Clinically, ISR accompanied by aggressive
AV progression was associated with poor long-term out-
omes after heart transplantation. Angiographic measures
howed close coupling on a patient-by-patient basis between
SR and coronary lesion progression at sites remote from the
tent, only in CAV patients, possibly suggesting common
nderlying mechanisms. Post-mortem examination of arteries
rom 2 patients demonstrated similar histopathological char-
cteristics within restenotic lesions and non-stented CAV sites.
revious studies of PCI in CAV. Initial experience with
alloon angioplasty as a treatment for CAV established the
easibility and safety of percutaneous transluminal coronary
ngioplasty in this setting but was discouraging because of
igh restenosis rates (15). Coronary stenting with bare-
etal stents, superior to balloon angioplasty in treating
ative coronary artery disease (16), has also favorably influ-
nced long-term patency after PCI in patients with CAV
ing significant stenosis of the ramus intermedius (arrow) and minimal
ead); (B) post-stent angiogram showing good angiographic result aftershow
rowhter stenting, showing focal in-stent restenosis of the ramus (arrow) with
f the left anterior descending artery (arrowhead).
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August 1, 2006:453–61 Stent Restenosis and Transplant Vasculopathy3,5,7). Doshi et al. (7) retrospectively described their
xperience with coronary stenting at 2 medical centers and
eported that 9 of 11 lesions treated with stents were patent
t follow-up. Benza et al. (3) recently reported 8-month
ngiographic restenosis rates of 39% in 73 lesions, consis-
ent with our findings of angiographic restenosis in 37.8% of
esions after 1 year.
orrelation of ISR with CAV progression. Of particular
nterest is our finding, through core lab angiographic eval-
ations of patients from 2 centers with busy heart transplant
rograms, of the close association between development of
SR and CAV progression in a control non-stented segment
rom the same patient over the same time period. Patients
igure 4. Photomicrographs show: (A) Ramus intermedius stent; (B) non
) Carstair’s fibrin stain, and 3) Sirius red collagen stain demonstrate: in A
imilar-appearing intimal thickening consisting of fibrotic, collagen-rich, h
nd the non-intervened artery. 4) Immunohistochemical CD-68 staining (p
egment neointima (A) and non-intervened allograft vasculopathy (B). P
C) and non-intervened, marginal branch (D) of Case 2, and high-powe
arginal branch transplant vasculopathy demonstrate similar fibrotic hypoith ISR also exhibited marked CAV disease progression, pnd there was a close continuous correlation across all
atients, with or without restenosis, between LL in the
tented segment and in the non-treated control sites. This
oupling between ISR and non-intervened coronary artery
isease was unique to post-transplant patients and notably
bsent in a cohort of native atherosclerosis patients under-
oing PCI with angiographic follow-up. Furthermore, the
ong-term prognosis of patients with restenosis and CAV
rogression was significantly worse than that of heart
ransplant patients without evidence of restenosis, despite
imilar baseline clinical characteristics.
AV progression and long-term survival. The develop-
ent of CAV is a major clinical concern because of its
vened, diagonal branch of Case 1 patient. 1) Verhoeff tissue elastin stain,
re in-stent restenosis and in B, diffuse cardiac allograft vasculopathy with
ellular matrix with adventitial thickening and fibrosis in both the stented
e reaction color is brown) showing macrophage infiltration in both stented
icrographs (Verhoeff tissue elastin stain) of the circumflex artery stent
of the in-stent restenosis neointima (C’); both in-stent restenosis and
ar neointima proliferation.-inter
, seve
ypoc
ositiv
hotom
r viewrogressive nature and threat to long-term cardiac allograft
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Stent Restenosis and Transplant Vasculopathy August 1, 2006:453–61urvival. Once mild CAV is identified angiographically, the
ikelihood of progression to severe disease within 5 years is
ncreased significantly (17). Furthermore, approximately
0% of patients noted to have moderate coronary lesions on
heir annual angiogram will have disease progression a year
ater, and remain at an increased risk of sudden death and
eed for revascularization (1,18).
Recently, a multicenter intravascular ultrasound (IVUS)
tudy suggested that progression of intimal thickening in
he first year after transplantation appears to be a reliable
urrogate marker for development of late angiographic
AV, with subsequent increased rates of MI and mortality
19). A non-randomized retrospective analysis of patients
ith angiographically evident CAV noted that allograft
urvival was not altered by PCI (combining both balloon
ngioplasty and stenting procedures) or medical therapy (2).
Our finding of poor clinical outcomes in CAV patients
ith ISR (related to CAV but not to the restenosis per se)
s consistent with these observations. Our angiographic
bservation of the close correlation between restenosis and
isease progression at remote coronary segments, may
ermit better selection of revascularization options (bypass
urgery vs. drug-eluting stents [DES] vs. bare-metal stents)
ased on the rapidity of a given patient’s disease progression.
ystemic therapy aimed at modifying CAV may be partic-
larly appropriate in this subgroup of patients. In particular,
subgroup of patients with aggressive CAV may be poorly
erved by PCI because of high restenosis rates with con-
omitant rapid CAV progression at non-intervened coro-
ary segments. Prospective identification of such patients
ay call for therapeutic options other than, or in addition
o, PCI. What effect DES treatment of obstructive or
on-obstructive focal CAV will have is of great interest.
any current and future DES are employing macrolide
ntibiotics (sirolimus, everolimus, and zotarolimus, among
thers), and there is reason to expect a beneficial effect on
L and restenosis in CAV patients, as has been seen in
therosclerosis patients. However, as a stand-alone focal
reatment, this may not translate into long-term clinical
enefit in patients at risk for restenosis, as these patients
uffer from rapid CAV progression elsewhere in the coro-
ary vasculature.
athophysiology features of ISR and CAV. Cardiac al-
ograft vasculopathy is a diffuse, proliferative disease of the
oronary neointima, the pathogenesis of which is not fully
nderstood. A growing body of literature supports a para-
igm whereby intimal thickening is a consequence of
ultifactorial endothelial damage from both immune and
on-immune causes, followed by an increased inflammatory
esponse driving vascular smooth muscle cell proliferation
1,8,20–22). This process is clearly distinct from conven-
ional atherosclerosis. In-stent restenosis in native coronary
rtery disease, likewise, is pathophysiologically dissimilar
rom de novo atherosclerosis. Indeed, in-stent neointimal
roliferation is thought also to involve endothelial damage, pascular smooth muscle cell proliferation/migration, and
nflammation (14,23,24).
In the present analysis, we were able to examine simul-
aneously the histopathology of ISR and CAV from 2 heart
ransplant patients. While these data are limited in number
nd lack a full analysis of cellular and humeral inflammatory
esponse, they provide a side-by-side histopathology view of
SR and concomitant CAV. Severe in-stent intimal prolif-
ration paralleled substantial intimal thickening of a non-
tented segment in both patients. The CAV and restenotic
egments shared common histological features of concentric
eointimal hyperplasia without any significant lipid or foam
ell component. Both stented and non-stented segments
ad a notably fibrotic neointima, with collagen-rich ele-
ents and the presence of some inflammatory (CD68)
ells. Marked adventitial thickening and fibrosis were also
bserved in both. A single previous histologic description of
SR in CAV noted a paucity of inflammatory cells with
arked hypocellularity and similar collagen-rich fibrotic
lements in the in-stent neointima (25). Interestingly,
ognestad et al. (26) recently compared immune activation
n blood samples from a small group of patients with native
therosclerosis and transplant vasculopathy undergoing cor-
nary interventions. Although a different immune activation
rofile was noted between the 2 groups, an inappropriate
nflammatory reactivity was found to predispose to resteno-
is in both groups.
tudy limitations. The present observational study is ret-
ospective, non-randomized, and limited to only those
atients with severe CAV requiring revascularization. Al-
hough we used well-established quantitative angiographic
nalytic methods, angiography is known to underestimate
he extent of CAV, especially in comparison to IVUS.
ntravascular ultrasound data were not routinely acquired in
he reported patients. Therefore, we cannot exclude a role
or negative vascular remodeling in addition to intimal
yperplasia at the non-PCI sites of CAV, especially as
ifferent mechanisms of lumen loss may hold sway during
he early and late phases after transplantation (27). How-
ver, our histologic studies as well as prior reports suggest
hat intimal hyperplasia rather than negative vascular re-
odeling was the predominant mechanism of LL ISR and
robably CAV. Although non-invasive coronary imaging
as a potential role as an alternative to conventional coro-
ary angiography in the surveillance of transplant vascu-
opathy (28), we do not have such imaging data in our
atient population.
The histology data provided are significantly limited in
umbers, and although immunostaining for tissue mac-
ophages is presented, this is far from being a compre-
ensive analysis of inflammatory cellular and cytokine
esponse to stent injury and CAV. Finally, the patients
eported underwent PCI before widespread availability
f DES.
onclusions. Coronary stenting in cardiac transplant
atients has excellent initial procedural success but high
r
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orrelation exists between angiographic progression of
AV at a non-PCI site and ISR after heart transplanta-
ion, in marked contrast to the lack of any such associa-
ion in a control group of native atherosclerosis patients
ndergoing stenting with similar angiographic follow-up.
inally, patients with restenosis have greater cardiac
ortality related to rapid CAV progression than those
ithout restenosis. The preferred treatment modality for
atients with rapidly progressive CAV remains enig-
atic, and may continue to be so despite improvements
n PCI outcomes, which DES may bring. Treatment
trategies for heart transplant patients with CAV, partic-
larly rapidly progressive CAV, need to address the
idespread progressive nature of this disease, rather than
nly the initial focal coronary lesion.
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